In Nebraska, a 48-year-old woman with an “unremarkable” past medical history was taken to the ER after three days of malaise and abdominal pain. She remains critically ill.
Another woman,age 38, also presented with cerebral venous sinus thrombosis, or CVST. She has not recovered.
A 59-year-old woman with no known coronary artery disease who received the J&J vaccine presented with extensive deep venous thrombosis on her left side seven days after taking the shot. She has not recovered.
An 18-year-old in Nevada with unknown risk factors received the vaccine, and two weeks later presented with CVST (cerebral venous sinus thrombosis) with hemorrhage. She has not yet recovered.
A 26-year-old woman with obesity in the New Jersey-Pennsylvania area received the J&J shot and seven days later presented with symptom onset. She has since been discharged from the hospital.
Based upon increased understanding of who may be at risk, panel members acknowledge the delicate balance between racing forward to beat the virus and its variants, versus slowing down and ensuring the safety and impact of the vaccine.
“This is so challenging because the impact of ACIP decisions on the global stage is clear,” said Dr. Grace Lee, co-chair of a panel on the committee. “I continue to feel we’re in a race against time and the variants but we need to do so in the safest possible way.”
The CDC says anyone who recently got the J&J vaccine should be aware of oncoming severe headaches, severe abdominal pain, or shortness of breath within a week to three weeks after Injection. They suggest seeking medical attention and mention your vaccine when doing so. Diagnostic tests should be completed to determine the appropriate use of the blood thinner Heparin during treatment.